FrancophonIA/ELRC3.0 huggingface dataset:
English: Bimatoprost 0.3 mg/ml eye drops, solution contains the preservative benzalkonium chloride, which may be absorbed by soft contact lenses.
Slovenian: Bimatoprost 0,3 mg/ml kapljice za oko, raztopina vsebuje konzervans benzalkonijev klorid, ki se lahko absorbira v mehke kontaktne leče.
English: CARTON CONTAINING THREE BOTTLES
Slovenian: ŠKATLA S TREMI PLASTENKAMI
English: In studies of bimatoprost 0.3 mg/ml in patients with glaucoma or ocular hypertension, it has been shown that the more frequent exposure of the eye to more than one dose of bimatoprost daily may decrease the IOP-lowering effect (see section 4.5).
Slovenian: Po študijah, bimatoprosta 0,3 mg/ml pri bolnikih z glavkomom ali okularno hipertenzijo, lahko večkratna izpostavljenost očesa več kot enemu odmerku bimatoprosta dnevno zmanjša učinek zniževanja očesnega tlaka (glejte poglavje 4.5).
English: LUMIGAN 0.3 mg/mL single-dose has not been tested in children under the age of 18 and therefore should not be used by patients under 18 years.
Slovenian: Ker zdravila LUMIGAN 0,3 mg/ml (enoodmerna oblika) niso preskušali pri otrocih, mlajših od 18 let, se pri bolnikih, mlajših od 18 let, ne sme uporabljati.
English: LUMIGAN 0.3 mg/mL single-dose also achieved equivalent IOP lowering efficacy with LUMIGAN 0.3 mg/mL (multi-dose formulation) in average eye IOP at each follow-up timepoint at weeks 2, 6 and 12.
Slovenian: Zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) je imelo tudi enakovredno učinkovitost pri zniževanju očesnega tlaka kot zdravilo LUMIGAN 0,3 mg/ml (večodmerna oblika) pri povprečnem očesnem tlaku pri pregledih čez 2, 6 in 12 tednov.
English: LUMIGAN 0.3 mg/mL single-dose has not been studied in patients wearing contact lenses.
Slovenian: Zdravila LUMIGAN 0,3 mg/ml (enoodmerna oblika) niso preučevali pri bolnikih, ki uporabljajo kontaktne leče.
English: The safety and efficacy of LUMIGAN in children aged 0 to less than 18 years has not been established.
Slovenian: Varnost in učinkovitost zdravila LUMIGAN pri otrocih, starih od 0 do manj kot 18 let, nista bili dokazani.
English: Vascular disorders not known hypertension
Slovenian: Žilne bolezni neznana pogostnost hipertenzija
English: No clinically relevant effects on heart rate and blood pressure have been observed in clinical trials.
Slovenian: Pri kliničnih preskušanjih niso opazili klinično pomembnih učinkov na srčni utrip in krvni tlak.
English: Talk to your doctor or pharmacist before you use LUMIGAN 0.1 mg/ml Talk to your doctor, if: - You have any breathing problems - You have liver or kidney problems - You have had a cataract surgery in the past - You have dry eye - You have or have had any problems with your cornea (front transparent part of the eye) - You wear contact lenses (see “Important information about some of the ingredients of
Slovenian: Pred začetkom uporabe zdravila LUMIGAN 0,3 mg/ml se posvetujte z zdravnikom ali farmacevtom: - Obvestite svojega zdravnika, če: - imate kakršnekoli težave z dihanjem, - če imate težave z jetri ali ledvicami, - če ste bili v preteklosti operirani za sivo mreno, - če imate suhe oči, - če imate ali ste imeli težave z roženico (sprednji, prozorni del očesa), - če uporabljate kontaktne leče (glejte poglavje »Pomembne informacije o nekaterih sestavinah zdravila LUMIGAN 0,3 mg/ml«),
English: MARKETING AUTHORISATION NUMBER
Slovenian: ŠTEVILKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: Approximately 4 % of patients discontinued due to any adverse event in the 12-month study.
Slovenian: V 12-mesečni študiji je zaradi neželenih dogodkov zdravilo prenehalo jemati približno 4 % bolnikov.
English: • Increasing tears
Slovenian: • povečano solzenje,
English: LUMIGAN may cause your eyelashes to darken and grow, and cause the skin around the eyelid to darken too.
Slovenian: Zdravilo LUMIGAN lahko povzroči temnenje in rast trepalnic ter temnenje kože okrog vek.
English: In patients with a history of mild liver disease or abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin at baseline, bimatoprost 0.3 mg/ml eye drops, solution had no adverse effect on liver function over 24 months.
Slovenian: Pri bolnikih z anamnezo blage bolezni jeter ali nenormalnih vrednosti alanin-aminotransferaze (ALT), aspartat-aminotransferaze (AST) in/ali celokupnega bilirubina, bimatoprost 0,3 mg/ml kapljice za oko, raztopina v 24 mesecih ni imela neželenega učinka na delovanje jeter.
English: LUMIGAN 0.3 mg/mL single-dose eye drops are used to reduce high pressure in the eye.
Slovenian: LUMIGAN 0,3 mg/ml, kapljice za oči, (enoodmerna oblika) se uporablja za zmanjševanje previsokega očesnega tlaka.
English: Conjunctival hyperaemia, growth of eyelashes, and eye pruritus were statistically significantly higher with bimatoprost than with latanoprost, however, the discontinuation rates due to adverse events were low with no statistically significant difference.
Slovenian: Hiperemija veznice, rast trepalnic in očesni pruritus so bili statistično značilno višji pri bimatoprostu kot pri latanoprostu.
English: If you stop using LUMIGAN the pressure inside your eye may go up, therefore talk to your doctor before stopping this treatment.
Slovenian: Če zdravilo LUMIGAN prenehate uporabljati, se lahko očesni tlak zviša, zato se pred prenehanjem zdravljenja posvetujte z zdravnikom.
English: This dose expressed as mg/m2 is at least 210 times higher than the accidental dose of one bottle of LUMIGAN 0.1 mg/ml eye drops, solution in a 10 kg child.
Slovenian: Ta odmerek, izražen kot mg/m2, je najmanj 210-krat višji kot nenamerno zaužit odmerek ene plastenke zdravila LUMIGAN 0,1 mg/ml kapljice za oko, raztopina, pri otroku, ki tehta 10 kg.
English: If LUMIGAN 0.3 mg/mL singledose is accidentally ingested, the following information may be useful: In short term oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day of bimatoprost did not produce any toxicity.
Slovenian: Če se zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) pomotoma zaužije, je lahko koristna naslednja informacija: v kratkoročnih študijah pri peroralnem zaužitju pri podganah in miših odmerki bimatoprosta do 100 mg/kg/dan niso povzročili toksičnosti.
English: Vascular disorders common hypertension
Slovenian: Žilne bolezni pogosti hipertenzija
English: The recommended dose is one drop in the affected eye(s) once daily, administered in the evening.
Slovenian: Priporočen odmerek je ena kapljica v prizadeto oko (oči) enkrat dnevno, zvečer.
English: Very common side effects These may affect one or more users in 10 Affecting the eye
Slovenian: Ti učinki se lahko pojavijo pri enem ali več od 10 bolnikov.
English: In studies of bimatoprost 0.3 mg/ml in patients with glaucoma or ocular hypertension, it has been shown that the more frequent exposure of the eye to more than one dose of bimatoprost daily may decrease the IOP-lowering effect.
Slovenian: Po študijah bimatoprosta 0,3 mg/ml pri bolnikih z glavkomom ali okularno hipertenzijo lahko večkratna izpostavljenost očesa več kot enemu odmerku bimatoprosta dnevno zmanjša učinek zniževanja očesnega tlaka.
English: In patients with a history of mild liver disease or abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin at baseline, bimatoprost 0.3 mg/mL eye drops (multi-dose formulation), solution had no adverse effect on liver function over 24 months.
Slovenian: Pri bolnikih z anamnezo blage bolezni jeter ali nenormalnih vrednosti alanin-aminotransferaze (ALT), aspartat-aminotransferaze (AST) in/ali celokupnega bilirubina, bimatoprost 0,3 mg/ml kapljice za oko (večodmerna oblika), raztopina v 24 mesecih ni imela neželenega učinka na delovanje jeter.
English: Turn the single-dose container upside down and squeeze it to release 1 drop into the affected eye(s).
Slovenian: Enoodmerni vsebnik obrnite navzdol, stisnite ga in vkapajte po eno kapljico v vsako prizadeto oko.
English: Uncommon side effects These may affect 1 to 9 users in 1000 Affecting the eye
Slovenian: Občasni neželeni učinki Ti učinki se lahko pojavijo pri 1 do 9 od 1000 bolnikov.
English: There is a potential for the IOP-lowering effect of prostaglandin analogues (e.g. LUMIGAN) to be reduced in patients with glaucoma or ocular hypertension when used with other prostaglandin analogues (see section 4.4).
Slovenian: Pri bolnikih z glavkomom ali okularno hipertenzijo se lahko pri uporabi z drugimi analogi prostaglandina zmanjša učinek zniževanja očesnega tlaka analogov prostaglandina (npr. zdravila LUMIGAN; glejte poglavje 4.4).
English: • Weakness
Slovenian: • slabost,
English: • Feeling of sickness
Slovenian: • občutek slabosti.
English: LUMIGAN 0.3 mg/mL single-dose may cause your eyelashes to darken and grow, and cause the skin around the eyelid to darken too.
Slovenian: Zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) lahko povzroči temnenje in rast trepalnic ter temnenje kože okrog vek.
English: OUTER CARTON CONTAINING 30 SINGLE-DOSE CONTAINERS
Slovenian: ZUNANJA ŠKATLA S 30 ENOODMERNIMI VSEBNIKI
English: In clinical studies, LUMIGAN was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
Slovenian: Pri kliničnih študijah so zdravilo LUMIGAN uporabili sočasno s številnimi drugimi očesnimi antagonisti adrenergičnih receptorjev beta, brez dokazov o interakcijah.
English: LUMIGAN 0.3 mg/mL single-dose achieved non-inferior IOP-lowering efficacy to LUMIGAN 0.3 mg/mL (multi-dose formulation) for worse eye IOP change from baseline in patients with glaucoma or ocular hypertension.
Slovenian: Zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) ni bilo manj učinkovito pri znižanju očesnega tlaka kot zdravilo LUMIGAN 0,3 mg/ml (večodmerna oblika) pri hujših spremembah očesnega tlaka od osnovne vrednosti pri bolnikih z glavkomom ali očesno hipertenzijo.
English: Therefore, LUMIGAN should be used with caution in patients with known risk factors for macular oedema (e.g. aphakic patients, pseudophakic patients with a torn posterior lens capsule).
Slovenian: Zato je treba pri bolnikih z znanimi dejavniki tveganja za makularne edeme (npr. bolniki z afakijo, bolniki s psevdoafakijo s poškodovano posteriorno lečno kapsulo) zdravilo LUMIGAN uporabljati previdno.
English: If you stop using LUMIGAN 0.3 mg/mL single-dose the pressure inside your eye may go up, therefore talk to your doctor before stopping this treatment.
Slovenian: Če zdravilo LUMIGAN 0,3 mg/ml prenehate uporabljati, se lahko očesni tlak zviša, zato se pred prenehanjem zdravljenja posvetujte z zdravnikom.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Slovenian: DATUM PRIDOBITVE / PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: If you forget to use LUMIGAN 0.3 mg/mL single-dose If you forget to use this medicine, use a single drop as soon as you remember, and then go back to your regular routine.
Slovenian: Če ste pozabili uporabiti zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) Če ste pozabili uporabiti zdravilo, si vkapajte eno kapljico takoj, ko se spomnite in nadaljujte zdravljenje v običajnih razmikih.
English: This dose expressed as mg/m2 is at least 70-times higher than the accidental dose of one bottle of LUMIGAN 0.3 mg/ml eye drops, solution in a 10 kg child.
Slovenian: Ta odmerek, izražen kot mg/m2, je najmanj 70-krat višji kot nenamerno zaužiti odmerek ene plastenke zdravila LUMIGAN 0,3 mg/ml kapljice za oko, raztopina, pri otroku, ki tehta 10 kg.
English: • Swelling of the see-through layer that covers the eye
Slovenian: • otekanje prozorne plasti, ki pokriva oko,
English: Clear, single-dose Low Density Polyethylene (LDPE) containers with a twist-off tab.
Slovenian: Prozorni enoodmerni vsebniki iz polietilena nizke gostote s pokrovčkom na zasuk.
English: Reduction of the intraocular pressure starts approximately 4 hours after the first administration and maximum effect is reached within approximately 8 to 12 hours.
Slovenian: Največji učinek je dosežen v približno 8 do 12 urah in traja najmanj 24 ur.
English: The recommended dose is one drop of LUMIGAN in the evening, once daily in each eye that needs treatment.
Slovenian: Priporočeni odmerek je ena kapljica zdravila LUMIGAN enkrat dnevno, ki jo je treba zvečer vkapati v vsako zdravljeno oko.
English: At 3 months, the incidence of iris hyperpigmentation with bimatoprost 0.3 mg/mL single dose was 0.3%.
Slovenian: Po 3 mesecih je bila incidenca povečane pigmentacije irisa z bimatoprostom 0,3 mg/ml (enoodmerna oblika) 0,3 %.
English: LUMIGAN should only be applied to the eye.
Slovenian: Zdravilo LUMIGAN uporabljajte le za vkapanje v oko.
English: • conjunctival hyperaemia (mostly trace to mild and thought to be of a non-inflammatory nature) in up to 44% in the first year with the incidence of new reports decreasing to 13% at 2 years and 12% at 3 years
Slovenian: • hiperemija veznice (najpogosteje komaj opazna do blaga in domnevno nevnetnega izvora) pri do 44 % bolnikov v prvem letu, z upadom števila novih poročil na 13 % pri 2 letih in na 12 % pri 3 letih;
English: LUMIGAN has not been tested in children under the age of 18 and therefore LUMIGAN should not be used by patients under 18 years.
Slovenian: Ker zdravila LUMIGAN niso preskušali pri otrocih, mlajših od 18 let, se zdravila LUMIGAN pri bolnikih, mlajših od 18 let ne sme uporabljati.
English: Less than 9 % of patients discontinued due to any adverse event in the first year with the incidence of additional patient discontinuations being 3 % at both 2 and 3 years.
Slovenian: Manj kot 9 % bolnikov je prekinilo zdravljenje zaradi kateregakoli neželenega učinka v prvem letu s 3 % porastom števila prekinitev zdravljenja bolnikov v 2. in 3. letu.
English: In a 3 month clinical study, approximately 29% of patients treated with LUMIGAN 0.3 mg/mL singledose experienced adverse reactions.
Slovenian: V 3-mesečni klinični študiji je približno 29 % bolnikov, ki je prejemalo zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika), imelo neželene učinke.
English: At 12 months, the incidence of iris hyperpigmentation with bimatoprost 0.1 mg/ml eye drops, solution was 0.5%.
Slovenian: Po 12 mesecih je bila incidenca hiperpigmentacije irisa z bimatoprostom 0,1 mg/ml kapljicami za oko, raztopino, 0,5 %.
English: There is a potential for hair growth to occur in areas where LUMIGAN solution comes repeatedly in contact with the skin surface.
Slovenian: Na območjih, kjer je raztopina zdravila LUMIGAN večkrat v stiku s površino kože, se lahko pojavi rast dlak.
English: Small amounts of hydrochloric acid or sodium hydroxide may be added to keep the level of acid (pH levels) normal.
Slovenian: Za ohranjanje normalne ravni kislosti (raven pH) so lahko dodane majhne količine klorovodikove kisline ali natrijevega hidroksida.
English: Limited experience is available in patients with open-angle glaucoma with pseudoexfoliative and pigmentary glaucoma, and chronic angle-closure glaucoma with patent iridotomy.
Slovenian: Omenjene izkušnje so na voljo pri bolnikih z glavkomom odprtega zakotja s psevdoeksfoliativnim in pigmentnim glavkomom ter kroničnim glavkomom zaprtega zakotja s patentirano iridotomijo.
English: OUTER CARTON CONTAINING 90 SINGLE-DOSE CONTAINERS
Slovenian: ŠKATLA Z 90 ENOODMERNIMI VSEBNIKI
English: If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.
Slovenian: Če bolnik uporablja več različnih zdravil za oko za lokalno uporabo, jih je potrebno aplicirati v razmiku najmanj 5 minut.
English: Do not use LUMIGAN 0.1 mg/ml: - if you are allergic to bimatoprost or any of the other ingredients of this medicine (listed in section
Slovenian: Ne uporabljajte zdravila LUMIGAN 0,1 mg/ml: - če ste alergični na bimatoprost ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: On combining the data from phase III monotherapy and adjunctive LUMIGAN 0.3 mg/ml usage, the most frequently reported adverse reactions were:
Slovenian: S kombinacijo podatkov iz III. faze monoterapije in adjuvantne terapije z zdravilom LUMIGAN 0,3 mg/ml, so bila najpogostejša poročila o neželenih učinkih, kot posledica zdravljenja:
English: LUMIGAN 0.3 mg/ml is contraindicated in patients who have had a suspected previous adverse reaction to benzalkonium chloride that has led to discontinuation.
Slovenian: Zdravilo LUMIGAN 0,3 mg/ml je kontraindicirano pri bolnikih, ki so v preteklosti že imeli domneven neželen učinek na benzalkonijev klorid, zaradi katere so prenehali jemati zdravilo.
English: • Inflammation within the eye
Slovenian: • vnetje v notranjosti očesa,
English: In a 6-month clinical study with LUMIGAN 0.3 mg/ml, versus latanoprost, a statistically superior reduction in morning mean IOP (ranging from -7.6 to -8.2 mmHg for bimatoprost versus -6.0 to -7.2 mmHg for latanoprost) was observed at all visits throughout the study.
Slovenian: V 6-mesečni primerjalni klinični študiji v kateri so zdravilo LUMIGAN 0,3 mg/ml primerjali z latanoprostom, so opazili statistično značilno jutranje znižanje povprečnega očesnega tlaka (v razponu od -7,6 do -8,2 mmHg za bimatoprost v primeravi z -6,0 do -7,2 mmHg za latanoprost) pri vseh vizitah v času študije.
English: Do not use LUMIGAN 0.3 mg/ml: - if you are allergic to bimatoprost or any of the other ingredients of this medicine (listed in section
Slovenian: Ne uporabljajte zdravila LUMIGAN 0,3 mg/ml: - če ste alergični na bimatoprost ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Nervous system disorders common headache
Slovenian: Bolezni živčevja pogosti glavobol
English: If you use more LUMIGAN 0.1 mg/ml than you should If you use more LUMIGAN than you should, it is unlikely to cause you any serious harm.
Slovenian: Če ste uporabili večji odmerek zdravila LUMIGAN 0,1 mg/ml, kot bi smeli Če ste uporabili večji odmerek zdravila LUMIGAN, kot bi smeli, je malo verjetno, da bo to povzročilo kakršnokoli resnejšo poškodbo.
English: In a 6-month clinical study with LUMIGAN 0.3 mg/mL (multi-dose formulation), versus latanoprost, a statistically superior reduction in morning mean IOP (ranging from -7.6 to -8.2 mmHg for bimatoprost versus -6.0 to -7.2 mmHg for latanoprost) was observed at all visits throughout the study.
Slovenian: V 6-mesečni primerjalni klinični študiji v kateri so zdravilo LUMIGAN 0,3 mg/ml (večodmerna oblika) primerjali z latanoprostom, so opazili statistično značilno jutranje znižanje povprečnega očesnega tlaka (v razponu od -7,6 do -8,2 mmHg za bimatoprost v primerjavi z -6,0 do -7,2 mmHg za latanoprost) pri vseh vizitah v času študije.
English: In addition to the side effects for LUMIGAN 0.1 mg/ml, the following side effects have been seen with another medicine containing a higher strength of bimatoprost (0.3 mg/ml):
Slovenian: Poleg neželenih učinkov zdravila LUMIGAN 0,1 mg/ml, so pri drugih zdravilih, ki vsebujejo večje koncentracije bimatoprosta (0,3 mg/ml), opazili naslednje neželene učinke:
English: If you stop using LUMIGAN 0.3 mg/mL single-dose LUMIGAN 0.3 mg/mL single-dose should be used every day to work properly.
Slovenian: Če ste prenehali uporabljati zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) Zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) je treba uporabljati redno vsak dan, da bi delovalo pravilno.
English: • Darker skin colour around the eye
Slovenian: • temnejša koža okrog očesa,
English: In clinical studies, LUMIGAN 0.3 mg/mL (multi-dose formulation) was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
Slovenian: Pri kliničnih študijah so zdravilo LUMIGAN 0,3 mg/ml (večodmerna oblika) uporabili sočasno s številnimi drugimi očesnimi antagonisti adrenenergičnih receptorjev beta brez dokazov o interakcijah.
English: LUMIGAN has not been tested in children under the age of 18 and therefore should not be used by patients under 18 years.
Slovenian: Ker zdravila LUMIGAN niso preskušali pri otrocih, mlajših od 18 let, se zdravila pri bolnikih, mlajših od 18 let ne sme uporabljati.
English: LUMIGAN 0.1 mg/ml is contraindicated in patients who have had a suspected previous adverse reaction to benzalkonium chloride that has led to discontinuation.
Slovenian: Zdravilo LUMIGAN 0,1 mg/ml je kontraindicirano pri bolnikih, ki so v preteklosti že imeli domnevno neželen učinek na benzalkonijev klorid, zaradi katere so prenehali uporabljati zdravilo.
English: In clinical studies, bimatoprost 0.3 mg/ml, eye drops, solution was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
Slovenian: Pri kliničnih študijah so bimatoprost 0,3 mg/ml, kapljice za oko, raztopina uporabili sočasno s številnimi drugimi očesnimi antagonisti adrenergičnih receptorjev beta, brez dokazov o interakcijah.
English: On combining the data from phase III monotherapy and adjunctive LUMIGAN 0.3 mg/mL (multi-dose formulation) usage, the most frequently reported adverse reactions were:
Slovenian: S kombinacijo podatkov iz III. faze monoterapije in adjuvantne terapije z zdravilom LUMIGAN 0,3 mg/ml (večodmerna oblika) so bila najpogostejša poročila o neželenih učinkih kot posledica zdravljenja:
English: These may affect 1 to 9 users in 100
Slovenian: Ti učinki se lahko pojavijo pri 1 do 9 od 100 bolnikov.
English: LUMIGAN 0.3 mg/mL single-dose may get into breast milk so you should not breast-feed while you are taking this medicine.
Slovenian: Zdravilo LUMIGAN 0,3 mg/ml (enoodmerna oblika) lahko prehaja v materino mleko, zato ženske, ki uporabljajo to zdravilo, ne smejo dojiti.
English: One ml of solution contains 0.05 mg benzalkonium chloride.
Slovenian: En mililiter raztopine vsebuje 0,05 mg benzalkonijevega klorida.
English: Respiratory, thoracic and mediastinal disorders not known asthma, asthma exacerbation, COPD exacerbation and dyspnoea
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora neznani astma, poslabšanje astme, poslabšanje kronične obstruktivne pljučne bolezni in dispneja
English: Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.
Slovenian: Neželeni učinki pri kapljicah za oko, ki vsebujejo fosfate O primerih kalcifikacije roženice so poročali v zelo redkih primerih, pri nekaterih bolnikih z znatnimi poškodbami roženice, ki so uporabljali kapljice za oko, ki vsebujejo fosfate.
English: If you use more LUMIGAN 0.3 mg/mL single-dose than you should If you use more of this medicine than you should, it is unlikely to cause you any serious harm.
Slovenian: Če ste uporabili večji odmerek zdravila LUMIGAN 0,3 mg/ml, kot bi smeli Če ste uporabili večji odmerek zdravila LUMIGAN, kot bi smeli, je malo verjetno, da bo to povzročilo kakršnokoli resnejšo poškodbo.
English: SINGLE-DOSE CONTAINER
Slovenian: ENOODMERNI VSEBNIK
English: Ocular use
Slovenian: okularna uporaba
English: Respiratory
Slovenian: Respiratorni sistem
English: After twice daily dosing with bimatoprost 0.3 mg/ml eye drops, solution, the mean AUC0-24hr value of 0.0634 ng•hr/ml bimatoprost in the elderly (subjects 65 years or older) were significantly higher than 0.0218 ng•hr/ml in young healthy adults.
Slovenian: Po odmerjanju bimatoprosta 0,3 mg/ml, kapljic za oko, raztopine dvakrat dnevno je bila povprečna AUC0-24hr vrednost bimatoprosta pri starejših (osebe stare 65 let ali starejše) 0,0634 ng•h/ml, kar je znatno več kot pri zdravih mlajših odraslih, kjer dosega 0,0218 ng•h/ml.
English: LUMIGAN may get into breast milk so you should not breast-feed while you are taking LUMIGAN.
Slovenian: Zdravilo LUMIGAN lahko prehaja v materino mleko, zato ženske, ki uporabljajo to zdravilo, ne smejo dojiti.
English: One ml of solution contains 0.2 mg benzalkonium chloride.
Slovenian: En mililiter raztopine vsebuje 0,2 mg benzalkonijevega klorida.
English: In addition to the adverse reactions seen with LUMIGAN 0.3 mg/mL single-dose, Table 3 lists additional adverse reactions that were seen with LUMIGAN 0.3 mg/mL (multi-dose formulation).
Slovenian: Poleg neželenih učinkov, ki so jih opažali pri uporabi zdravila LUMIGAN 0,3 mg/ml (enoodmerna oblika), preglednica 3 navaja dodatne neželene učinke, opažene pri uporabi zdravila LUMIGAN 0,3 mg/ml (večodmerna oblika).
English: These may affect 1 to 9 users in 1000
Slovenian: Ti učinki se lahko pojavijo pri 1 do 9 od 1000 bolnikov.